Abe Masaya, Fujii Nobuharu, Mizuhara Kentaro, Urata Tomohiro, Sumii Yuichi, Fujiwara Yuki, Seike Keisuke, Sando Yasuhisa, Nakamura Makoto, Fujii Keiko, Saeki Kyosuke, Meguri Yusuke, Asada Noboru, Ennishi Daisuke, Nishimori Hisakazu, Matsuoka Ken-Ichi, Maeda Yoshinobu
Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan.
Department of Transfusion Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan.
Leuk Res Rep. 2021 Apr 22;15:100241. doi: 10.1016/j.lrr.2021.100241. eCollection 2021.
Owing to the poor prognosis of relapsed or refractory acute lymphoblastic leukemia (ALL), hematopoietic stem cell transplantation (HSCT) followed by effective salvage therapy is required. Inotuzumab ozogamicin (INO) was developed for ALL refractory to standard chemotherapy. However, previous reports suggest that sinusoidal obstruction syndrome (SOS) risk increases in patients with HSCT receiving INO, especially with dual alkylating agents. We report a case of relapsed Philadelphia chromosome-negative B-ALL where the patient underwent haploidentical HSCT using fludarabine/total body irradiation conditioning and posttransplant cyclophosphamide. Successful engraftment was achieved without SOS development.
由于复发或难治性急性淋巴细胞白血病（ALL）的预后较差，需要进行造血干细胞移植（HSCT）并辅以有效的挽救治疗。因诺妥珠单抗（INO）是针对对标准化疗难治的ALL开发的。然而，先前的报告表明，接受INO的HSCT患者发生窦性阻塞综合征（SOS）的风险增加，尤其是联合使用烷化剂时。我们报告1例复发的费城染色体阴性B-ALL病例，该患者接受了使用氟达拉滨/全身照射预处理和移植后环磷酰胺的单倍体HSCT。成功实现植入且未发生SOS。
